Summary
Renal injury is a common side effect of the chemotherapeutic agent ifosamide. Current evidence suggests that the ifosfamide metabolite chloroacetaldehyde may contribute to this nephrotoxicity. The present study examined the effects of ifosfamide and chloroacetaldehyde on rabbit proximal renal tubule cells in primary culture. The ability of the uroprotectant medication sodium 2-mercaptoethanesulfonate (mesna) to prevent chloroacetaldehyde-induced renal cell injury was also assessed. Chloroacetaldehyde (12.5–150 µM) produced dose-dependent declines in neutral red dye uptake, ATP levels, glutathione content, and cell growth. Coadministration of mesna prevented chloroacetaldehyde toxicity while pretreatment of cells with the glutathione-depleting agent buthionine sulfoximine enhanced the toxicity of chloroacetaldehyde. Ifosfamide (1000–10 000 µM) toxicity was detected only at concentrations of 4000 µM or greater. Analysis of media collected from ifosfamide-treated cell cultures revealed the presence of several ifosfamide metabolites, demonstrating that renal proximal tubule cells are capable of biotransforming this chemotherapeutic agent. This primary renal cell culture system should prove useful in studying the cause and prevention of ifosfamide nephrotoxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aleo, M.; Taub, M.; Olson, J., et al. Primary cultures of rabbit renal proximal tubule cells: II. Selected phase I and phase II metabolic capacities. Toxicol. In Vitro 4:727–733; 1990.
Andreoli, S.; McAteer, J.; Seifert, S., et al. Oxidant-induced alteration in glucose and phosphate transport in LLC-PK1 cells: mechanisms of injury. Am. J. Physiol. 265:F377-F384; 1993.
Bohets, H. H.; Van Thielin, M. N.; Van Der Biest, I., et al. Cytotoxicity of mercury compounds in LLC-PK1, MDCK and human proximal tubule cells. Kidney Int. 47:395–403; 1995.
Borenfreund, E.; Puerner, J. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol. Lett. 24:119–124; 1985.
Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248–254; 1976.
Ho, P.; Zimmerman, K.; Wexler, L., et al. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 76:2557–2564; 1995.
Meier, T.; Allenbacher, A.; Mueller, E., et al. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna. Anti-Cancer Drugs 5:403–409; 1994.
Mohrmann, M.; Pauli, A.; Ritzer, M., et al. Inhibition of sodium-dependent transport systems in LLC-PK1 cells by metabolites of ifosfamide. Renal Physiol. Biochem. 15:289–301; 1992.
Mohrmann, M.; Ansorge, S.; Schmich, U., et al. Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture. Pediatr. Nephrol. 8:157–163; 1994.
Mohrmann, M.; Kupper, N.; Schonfeld, B., et al., Ifosfamide and mesna: effects on the Na/H exchanger in renal epithelial cells in culture. Renal Physiol. Biochem. 18:118–127; 1995.
Mohrmann, M.; Ansorge, S.; Schmich, U., et al. Dithio-bis-mercaptoethanesulphonate (dimesna) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells. Pediatr. Nephrol. 8:458–465; 1994.
Nissim, I.; Weinberg, J. M. Glycine attentuates Fanconi syndrome induced by maleate or ifosfamide in rats. Kidney Int. 49:684–695; 1996.
Ormstad, K.; Orrenius, S.; Lastbom, T., et al. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res. 43:333–338; 1983.
Prozialeck, W. C.; Lamar, P.C. Effects of glutathione depletion on the cytotoxic actions of cadmium in LLC-PK1, cells. Toxicol. Appl. Pharmacol. 134:285–295; 1995.
Sakhrani, L. M.; Badie-Dezfooly, B.; Trizna, W., et al. Transport and metabolism of glucose by renal proximal tubular cells in primary culture. Am. J. Physiol. 246:F757-F764; 1984.
Skinner, R.; Sharkey, I.; Pearson, A., et al. Ifosfamide, mesna and nephrotoxicity in children. J. Clin. Oncol. 11:173–190; 1993.
Somani, S. M.; Ravi, R.; Rybak, L. P. Diethyldithiocarbamate protection against cisplatin nephrotoxicity. Drug Chem. Toxicol. 18:151–170; 1995.
Sood, C.; O’Brien, P. J. Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem. Pharmacol. 46:1621–1626; 1993.
Sood, C.; O’Brien, P. Chloroacetaldehyde-induced hepatocyte cytotoxicity: mechanisms for cytoprotection. Biochem. Pharmacol. 48:1025–1032; 1994.
Springate, J. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J. Appl. Toxicol. 17:75–79; 1997.
Springate, J.; Zamlauski-Tucker, M.; Lu, H., et al. Renal clearance of ifosfamide. Drug Metab. Dispos. 29:1081–1082; 1997.
Taub, M. Primary kidney cells. In: Pollard, J.; Walker, J., ed. Methods in molecular biology. Vol. 5. Animal cell culture. Clifton, NJ: Humana Press; 1990:189–196.
Wagner, T. Ifosfamide clinical pharmacokinetics. Clin. Pharmacokinet. 26:439–456; 1994.
Wang, J.; Chan, K. Identification of new metabolites of ifosfamide in rat urine using ion cluster technique. J. Mass. Spectrom. 30:675–683; 1995.
Zamlauski-Tucker, M.; Morris, M.; Springate, J. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol. Appl. Pharmacol. 129:170–175; 1994.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Springate, J., Chan, K., Lu, H. et al. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In Vitro Cell.Dev.Biol.-Animal 35, 314–317 (1999). https://doi.org/10.1007/s11626-999-0080-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11626-999-0080-y